23 stories mentioning SHA:688506Updated just now
Every FINWIRES story that references SHA:688506, newest first.
Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject for the Phase III clinical trial of T-Bren, according to a Shanghai bourse filing on Wednesday.The drug is being tested in combination with pertuzumab and trastuzumab for the treatment of HER2-positive recurrent or metastatic breast cancer.
Sichuan Biokin Pharmaceutical (SHA:688506) reported a 128% decrease in net profit in 2025 to 1.05 billion yuan from 3.71 billion yuan a year earlier.Earnings per share plunged to 2.61 yuan from 9.25 yuan, the pharmaceutical company said in a Shanghai bourse filing on Tuesday.Revenue slumped 57% to 2.52 billion yuan from 5.82 billion yuan.Biokin attributed the lackluster performance to a high comparison base as the revenue generated in 2024 benefited from the intellectual property cooperation agreement it reached with BMS on a product called Iza-bren.Shares of the company fell 3% in recent trade.
Sichuan Biokin Pharmaceutical's (SHA:688506) attributable net loss ballooned to 774.6 million yuan in the first quarter from 531.4 million yuan a year earlier.Loss per share likewise widened to 1.88 yuan from 1.33 yuan, the pharmaceutical company said in a Shanghai bourse filing on Tuesday.Revenue, however, jumped 40% to 94.6 million yuan from 67.4 million yuan, which Biokin attributed to increased market demand for its products.Shares of the company fell nearly 3% in recent trade.
Showing 21-23 of 23
